申请人:Rottapharm Biotech S.r.l.
公开号:US20150065523A1
公开(公告)日:2015-03-05
The present invention provides compounds of formula (I) including stereoisomers or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein X is NH, or O; Q is 5-6 membered heteroaryl group, which may be substituted by one or more substituents independently selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; A is phenyl or a 5-6 heteroaryl group, which may be substituted by one or more substituents independently selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; B may assume different meanings from A and is phenyl or a 5-6 membered heteroaryl group, which may be substituted by one or more substituents independently selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; and processes for their preparation, pharmaceutical compositions containing them and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.
本发明提供了公式(I)的化合物,包括其立体异构体或消旋体或混合物或其药学上可接受的盐:其中X是NH或O;Q是5-6成员杂环芳基,可以被一个或多个取代基独立地选自以下组成的一组取代基取代:C1-C4烷基,卤素,卤代C1-C4烷基,C1-C4烷氧基,CN;A是苯基或5-6杂环芳基,可以被一个或多个取代基独立地选自以下组成的一组取代基取代:C1-C4烷基,卤素,卤代C1-C4烷基,C1-C4烷氧基,CN;B可以与A有不同的含义,是苯基或5-6成员杂环芳基,可以被一个或多个取代基独立地选自以下组成的一组取代基取代:C1-C4烷基,卤素,卤代C1-C4烷基,C1-C4烷氧基,CN;以及它们的制备方法,含有它们的药物组合物以及它们作为Orexin 1和Orexin 2受体的双重拮抗剂的用途。